Infliximab: new indication. Psoriatic arthritis: just another intravenous me-too drug.
Minimal assessment, based on a non comparative prospective cohort study of single-agent therapy.
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000188:drug therapy*; D015331:Cohort Studies; D005602:France; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D007262:Infusions, Intravenous
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents